<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="203">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 16, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02071862</url>
  </required_header>
  <id_info>
    <org_study_id>CX-839-001</org_study_id>
    <nct_id>NCT02071862</nct_id>
  </id_info>
  <brief_title>Study of the Glutaminase Inhibitor CB-839 in Solid Tumors</brief_title>
  <official_title>Ph1 Study of the Safety, PK, and PDn of Escalating Oral Doses of the Glutaminase Inhibitor CB-839, as a Single Agent and in Combination With Standard Chemotherapy in Patients With Advanced and/or Treatment-Refractory Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Calithera Biosciences, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Calithera Biosciences, Inc</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Many tumor cells, in contrast to normal cells, have been shown to require the amino acid
      glutamine to produce energy for growth and survival. To exploit the dependence of tumors on
      glutamine, CB-839, a potent and selective inhibitor of the first enzyme in glutamine
      utilization, glutaminase, will be tested in this Phase 1 study in patients with solid
      tumors.

      This study is an open-label Phase 1 evaluation of CB-839 in patients with advanced solid
      tumors. The study will be conducted in 2 parts. Part 1 is a dose escalation study enrolling
      patients with locally-advanced, metastatic and/or refractory solid tumors to receive CB-839
      capsules orally twice or three times daily.

      In Part 2, patients with each of the following diseases will be enrolled: A) Triple-Negative
      Breast Cancer, B) Non-Small Cell Lung Cancer (adenocarcinoma), C) Renal Cell Cancer, D)
      Mesothelioma, E) Fumarate hydratase (FH)-deficient tumors, F) Succinate dehydrogenase
      (SDH)-deficient gastrointestinal stromal tumors (GIST), G) SDH-deficient non-GIST tumors, H)
      tumors harboring mutations in isocitrate dehydrogenase-1 (IDH1) or IDH2, and I) cMyc
      mutation tumors.

      As an extension of Part 2, patients will be treated with CB-839 in combination with standard
      chemotherapy. Combination groups include: Pac-CB, CBE, CB-Erl, and CBD. Pac-CB: patients
      with locally-advanced or metastatic TNBC will be treated with paclitaxel and CB-839. CBE:
      patients with advanced clear cell RCC or papillary RCC will be treated with everolimus in
      combination with CB-839. CB-Erl: patients with advanced NSCLC lacking the T790M EGFR
      mutation will be treated with erlotinib and CB-839. CBD: patients with NSCLC harboring KRAS
      mutation will be treated with docetaxel and CB-839.

      All patients will be assessed for safety, pharmacokinetics (plasma concentration of drug),
      pharmacodynamics (inhibition of glutaminase), biomarkers (biochemical markers that may
      predict responsiveness in later studies), and tumor response.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety and tolerability of CB-839: Incidence of adverse events</measure>
    <time_frame>Every 21 days from study start until disease progression or unacceptable toxicity, assessed for an expected average of 6 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Area under the Curve (AUC) of CB-839 concentration in blood</measure>
    <time_frame>Study Days 1, 15, and 22</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics: % inhibition of glutaminase in blood</measure>
    <time_frame>Study Days 1 and 15</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical activity: Change in tumor volume from baseline</measure>
    <time_frame>Every 9 weeks until disease progression or unacceptable toxicity, assessed for an expected average of 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">205</enrollment>
  <condition>Solid Tumors</condition>
  <condition>Triple-Negative Breast Cancer</condition>
  <condition>Non Small Cell Lung Cancer</condition>
  <condition>Renal Cell Carcinoma</condition>
  <condition>Mesothelioma</condition>
  <condition>Fumarate Hydratase (FH)-Deficient Tumors</condition>
  <condition>Succinate Dehydrogenase (SDH)-Deficient Gastrointestinal Stromal Tumors (GIST)</condition>
  <condition>Succinate Dehydrogenase (SDH)-Deficient Non-gastrointestinal Stromal Tumors</condition>
  <condition>Tumors Harboring Isocitrate Dehydrogenase-1 (IDH1) and IDH2 Mutations</condition>
  <condition>Tumors Harboring Amplifications in the cMyc Gene</condition>
  <arm_group>
    <arm_group_label>CB-839</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CB-839 administered as oral capsules two (BID) or three times daily (TID) in 21-day cycles until disease progression or unacceptable toxicity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pac-CB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CB-839 administered as oral capsules twice daily (BID) in combination with standard dose paclitaxel in 28-day cycles until disease progression or unacceptable toxicity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CBE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CB-839 administered as oral capsules twice daily (BID) in combination with standard dose everolimus in 28-day cycles until disease progression or unacceptable toxicity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CB-Erl</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CB-839 administered as oral capsules twice daily (BID) in combination with standard dose erlotnib in 28-day cycles until disease progression or unacceptable toxicity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CBD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CB-839 administered as oral capsules twice daily (BID) in combination with standard dose docetaxel in 21-day cycles until disease progression or unacceptable toxicity</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CB-839</intervention_name>
    <description>CB-839 monotherapy</description>
    <arm_group_label>CB-839</arm_group_label>
    <arm_group_label>Pac-CB</arm_group_label>
    <arm_group_label>CBE</arm_group_label>
    <arm_group_label>CB-Erl</arm_group_label>
    <arm_group_label>CBD</arm_group_label>
    <other_name>Glutaminase Inhibitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pac-CB</intervention_name>
    <description>CB-839 in combination with standard dose paclitaxel</description>
    <arm_group_label>Pac-CB</arm_group_label>
    <other_name>combo CB-839 and Paclitaxel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CBE</intervention_name>
    <description>CB-839 in combination with standard dose everolimus</description>
    <arm_group_label>CBE</arm_group_label>
    <other_name>combo CB-839 and everolimus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CB-Erl</intervention_name>
    <description>CB-839 in combination with standard dose erlotnib</description>
    <arm_group_label>CB-Erl</arm_group_label>
    <other_name>combo CB-839 and erlotnib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CBD</intervention_name>
    <description>CB-839 in combination with standard dose docetaxel</description>
    <arm_group_label>CBD</arm_group_label>
    <other_name>combo CB-839 and docetaxel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          -  Advanced malignancy that is relapsed and/or refractory to all available therapies
             that will confer clinical benefit. Newly diagnosed patients who refuse standard
             treatment regimens are also eligible

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1

          -  Life Expectancy of at least 3 months

          -  Adequate hepatic, renal, cardiac, and hematologic function

          -  Measurable disease by RECIST criteria

          -  Ability to provide written informed consent in accordance with federal, local, and
             institutional guidelines

        Exclusion Criteria

          -  Any other current or previous malignancy

          -  Chemotherapy, radiation therapy, hormonal therapy, immunotherapy or biological
             therapy, or investigational agent within 21 days

          -  Unable to receive medications oral medications

          -  Major surgery within 28 days before Cycle 1 Day 1

          -  Active infection requiring within 2 weeks prior to first dose of study drug

          -  Patients who have HIV, Hepatitis A, B or C or CMV reactivation

          -  Significant neurotoxicity/neuropathy (Grade 3 or higher) within 14 days of first dose
             of study drug

          -  Conditions that could interfere with treatment or protocol-related procedures
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Keith W Orford, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Calithera Biosciences, Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tina Woo</last_name>
    <phone>650-870-1028</phone>
    <email>twoo@calithera.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kate Doherty</last_name>
    <phone>650-870-1085</phone>
    <email>kdoherty@calithera.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UCSF Helen Diller Family Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Pamela Munster</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Melinda L Telli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Manish R Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute of Emory School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Taofeek K Owonikoko, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Othon Iliopoulos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>James W Mier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>George D Demetri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York City</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>James J Harding, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gary K Schwartz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania, Abramson Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Angela M DeMichele, MD MSCE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology, PLLC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jeffrey R Infante, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Funda Meric-Bernstam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.calithera.com</url>
  </link>
  <verification_date>January 2016</verification_date>
  <lastchanged_date>January 27, 2016</lastchanged_date>
  <firstreceived_date>February 14, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tumor metabolism</keyword>
  <keyword>Glutaminase</keyword>
  <keyword>Glutamine</keyword>
  <keyword>Tricarboxylic acid (TCA) cycle</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
    <mesh_term>Mesothelioma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
